Tort, Sera and Husein-ElAhmed, Husein (2023) Clinical question: For adults with opioid‐refractory cancer pain, what are the benefits and harms of nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD))? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4366.
External website: https://www.cochranelibrary.com/cca/doi/10.1002/cc...
For adults with opioid‐refractory cancer pain, moderate‐certainty evidence shows that nabiximols (THC and CBD applied in the oral mucosa at different doses and frequencies) probably result in little to no clinically relevant difference in patient global impression of improvement, pain intensity, or daily breakthrough opioid dosage when compared with placebo. Reviewers also reported little to no clinically relevant difference between groups in withdrawals due to adverse events or in serious adverse events. No studies assessed the number of participants reporting mild pain by 14 days after start of treatment.
B Substances > Cannabis product / compounds (Plant-derived cannabinoids) > Tetrahydrocannabinol (THC)
G Health and disease > Pathology > Cancer
J Health care, prevention, harm reduction and treatment > Treatment and maintenance > Treatment issues (pain management)
VA Geographic area > International
Repository Staff Only: item control page